Paydirt
BL
Insider

Bain Capital Life Sciences Investors, LLC

10% owner

Bain Capital Life Sciences Investors, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in Heartflow, Inc. (HTFL). Across 1 priced purchase filing, the average 21-session return was -26.2% from execution and -26.2% from disclosure (delay-adjusted; derived). The largest single filing was $56.1M of HTFL (2,000,000 sh × $28.05, as filed), executed Feb 4.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-26.2%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-26.2%
same 1 filings, from disclosure
Filings, ttm
2
1 buys · 1 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$81.1M
shares × price, as filed
Last traded
Apr 20
Filed Apr 20

Median ADV $45.9M across their filed names

Open performance
Volume by month
$56.1M$28.1M$0Oct 2024Apr 2025Oct 2025Apr 2026Jan 2025 · buys $1.7MFeb 2026 · sells $56.1MApr 2026 · buys $25.0M
Buys $26.7M Sells $56.1M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 1 filing Not on file 1 filing

Sector per market data · by filing · past 12 months

Most traded names
HTFL Heartflow, Inc. HTFL · 0 buys · 1 sell 1 filing KLRA KLRA KLRA · 1 buy · 0 sells 1 filing OLMA Olema Pharmaceuticals, Inc. OLMA · 1 buy · 0 sells 1 filing
Recent filings
KLRAPURCHASE Kailera Therapeutics, Inc. View filing → $25.0M
1,562,500 sh × $16.00
Exec Apr 20
Filed Apr 20 · 6:01 PM ET
HTFLSALE Heartflow, Inc. View filing → $56.1M
2,000,000 sh × $28.05
Exec Feb 4
Filed Feb 6 · 5:30 PM ET
OLMAPURCHASE Olema Pharmaceuticals, Inc. View filing → $1.7M
300,000 sh × $5.76
Exec Jan 8 2025
Filed Jan 13 2025 · 5:30 PM ET †